skip to content

Emmaus Life Sciences Announces Positive Top-Line Results of Its Phase 3 Clinical Trial For Sickle Cell Disease

March 19, 2014

Emmaus Life Sciences, Inc. today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.